With the latest well-tolerated pangenotypic direct acting antivirals (DAAs) (sofosbuvir/velpatasvir or glecaprevir/pibrentasvir) [2, 3], treatment duration decreased to 812 weeks, treatment success increased to 95100% and genotyping became dispensable [4]
Both Retatrutide (through caloric deficit) and Tesamorelin (through GH-mediated pathways) promote lipolysis
As a result, many patients feel less hungry and have fewer cravings
It has been widely studied in preclinical models for its potential to support tissue regeneration , angiogenesis , and inflammation modulation
During digestion, a variety of factors (meal quantity, nutrients, energy status, fermentation) feedback the nutrient load and energy status of the body towards the brain and control hunger and satiety circuits